Patents by Inventor Colin F. Spraggs

Colin F. Spraggs has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method of treating cancer
    Patent number: 10004742
    Abstract: Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLA-DRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: June 26, 2018
    Assignee: Novartis AG
    Inventors: Nan Bing, Linda Perry Briley, Laura R. Parham, Charles J. Cox, Colin F. Spraggs
  • Method of Treating Cancer
    Publication number: 20170065590
    Abstract: Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLA-DRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923.
    Type: Application
    Filed: November 21, 2016
    Publication date: March 9, 2017
    Inventors: Nan Bing, Linda Perry Briley, Laura R. Parham, Charles J. Cox, Colin F. Spraggs
  • Method of treating cancer
    Patent number: 9539257
    Abstract: Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLADRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: January 10, 2017
    Assignee: Novartis AG
    Inventors: Nan Bing, Linda Perry Briley, Laura R. Budde, Charles J. Cox, Colin F. Spraggs
  • METHOD OF TREATING CANCER
    Publication number: 20150231137
    Abstract: Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLADRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923.
    Type: Application
    Filed: February 27, 2015
    Publication date: August 20, 2015
    Inventors: Nan BING, Linda Perry Briley, Laura R. Budde, Charles J. Cox, Colin F. Spraggs
  • METHOD OF TREATING CANCER
    Publication number: 20150023953
    Abstract: Methods are provided for treating cancer in a patient in need thereof with a HER2 inhibitor, where such patients have certain polymorphisms in VEGFA, VEGFR or IGF1R.
    Type: Application
    Filed: January 31, 2013
    Publication date: January 22, 2015
    Inventor: Colin F. Spraggs
  • METHOD OF ADMINISTRATION AND TREATMENT
    Publication number: 20140221372
    Abstract: The present invention is directed to methods of administering foretinib or pharmaceutically acceptable salts or solvates thereof a c-Met inhibitor to a patient in need thereof comprising: determining whether said patient has less than 2 copies of the CAT haplotype in NR1I3 gene and/or the TT or CT genotype at the rs1045642 reference single nucleotide polymorphism in ABCB1 gene; and if said patient has less than 2 copies of the CAT haplotype in NR1I3 gene and/or the TT or CT genotype at the rs1045642 reference single nucleotide polymorphism in ABCB1 gene, administering to said patient a pharmaceutical composition comprising foretinib or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 6, 2014
    Publication date: August 7, 2014
    Applicant: GlaxoSmithKline Intellectual Property (NO 2.) Limited
    Inventors: Diptee Amit KULKARNI, Colin F Spraggs
  • METHOD OF TREATING CANCER
    Publication number: 20120156200
    Abstract: Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLA-DRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923.
    Type: Application
    Filed: August 20, 2010
    Publication date: June 21, 2012
    Applicant: SMITHKLINE BEECHAM (CORK) LTD.
    Inventors: Nan Bing, Linda Perry Briley, Laura R. Budde, Charles J. Cox, Colin F. Spraggs
  • Gene polymorphisms and response to treatment
    Publication number: 20030100479
    Abstract: Correlations between polymorphisms in various genes, and a subject's phenotypic response to treatment with a norepinephrine reuptake inhibitor are described. Methods of screening subjects to aid in the medical treatment of obesity are presented.
    Type: Application
    Filed: August 7, 2002
    Publication date: May 29, 2003
    Inventors: David J. Dow, Benjamin Duncan, Arlene R. Hughes, Penelope Manasco, Sreekumar G. Pillai, Theodre C. Spaulding, Colin F. Spraggs, Michael Stubbins, Chun-Fang Xu